AbbVie (ABBV) Income from Continuing Operations (2012 - 2026)
AbbVie (ABBV) reported Income from Continuing Operations of 697000000.0 for Q1 2026, down 45.93% year-over-year from 1289000000.0 in Q1 2025, and down 61.6% quarter-over-quarter from 1815000000.0 in Q4 2025.
AbbVie (ABBV) Income from Continuing Operations (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Income from Continuing Operations data on file, last reported at 697000000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 697000000.0, down 45.93% year-over-year; the trailing twelve-month figure through Mar 2026 was 3641000000.0 (down 13.37% YoY), and the FY2025 annual result was 4233000000.0, down 1.24% from the prior year.
- Income from Continuing Operations slipped to 697000000.0 in Q1 2026 per ABBV's latest filing, from 1815000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 4493000000.0 in Q1 2022 and troughed at 97000000.0 in Q1 2023.
- A 5-year average of 1505647058.82 and a median of 1372000000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 102.79% in 2024, then surged 7991.3% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 2472000000.0 in 2022, then sank by 66.67% to 824000000.0 in 2023, then plunged by 102.79% to 23000000.0 in 2024, then surged by 7991.3% to 1815000000.0 in 2025, then tumbled by 61.6% to 697000000.0 in 2026.
- Business Quant data shows ABBV's Income from Continuing Operations at 697000000.0 in Q1 2026, 1815000000.0 in Q4 2025, and 188000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 697.00 Mn |
| Dec 31, 2025 | 1.82 Bn |
| Sep 30, 2025 | 188.00 Mn |
| Jun 30, 2025 | 941.00 Mn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | -23.00 Mn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.37 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 824.00 Mn |
| Sep 30, 2023 | 1.78 Bn |
| Jun 30, 2023 | 2.03 Bn |
| Mar 31, 2023 | -97.00 Mn |
| Dec 31, 2022 | 2.47 Bn |
| Sep 30, 2022 | 3.95 Bn |
| Jun 30, 2022 | 928.00 Mn |
| Mar 31, 2022 | 4.49 Bn |
| Dec 31, 2021 | 4.05 Bn |
| Sep 30, 2021 | 3.18 Bn |
| Jun 30, 2021 | 769.00 Mn |